Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Oct 28:13:176.
doi: 10.1186/1471-2431-13-176.

Respective effects of phlebotomy losses and erythropoietin treatment on the need for blood transfusion in very premature infants

Odile Becquet, Delphine Guyot, Philippe Kuo, Françoise Pawlotsky, Marianne Besnard, Micheline Papouin, Alexandre Lapillonne  1
Affiliations
Comparative Study

Respective effects of phlebotomy losses and erythropoietin treatment on the need for blood transfusion in very premature infants

Odile Becquet et al. BMC Pediatr. .

Abstract

Background: The benefit to risk ratio of the treatment with erythropoietin (EPO) as a means of limiting the number of transfusions in very preterm infants during hospitalization, seems to be modest since the adoption of restrictive transfusion criteria and of policy limiting phlebotomy losses. We therefore aim to evaluate the factors associated with the number of late blood transfusion in very preterm infants in a unit where the routine use of EPO has been discontinued.

Methods: A comparative "before-after" study was carried out in premature infants born before 32 weeks postmenstrual age (PMA), over a period of one year before (EPO group) and one year after (non-EPO group) the discontinuation of EPO therapy.

Results: A total of 48 infants were included in the study (EPO = 21; non-EPO = 27). The number of infants transfused after the 15 day of life (D15) and the number of transfusions per infant after D15 were not significantly different between the two groups. In a multivariate analysis, the gestational age and the volume of blood drawn off during the first month of life significantly influenced the need for transfusions after the 15th day of life, independently of the treatment with EPO. The hemoglobin levels measured at different times of hospitalization (median postnatal age: 16, 33 and 67 days) were not significantly different between the two groups.

Conclusions: Our study shows that the discontinuation of EPO did not change the number of late transfusions. Even when a policy limiting phlebotomy losses is used, blood loss is an important and independent risk factor for late transfusion of very preterm infants.

PubMed Disclaimer

References

    1. Halperin DS, Wacker P, Lacourt G, Felix M, Babel JF, Aapro M, Wyss M. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J Pediatr. 1990;116(5):779–786. doi: 10.1016/S0022-3476(05)82671-X. - DOI - PubMed
    1. Messer J, Haddad J, Donato L, Astruc D, Matis J. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics. 1993;92(4):519–523. - PubMed
    1. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, Halliday HL, Versmold HT, Moriette G, Jorch G. et al.The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. The New England journal of medicine. 1994;330(17):1173–1178. - PubMed
    1. Soubasi V, Kremenopoulos G, Diamandi E, Tsantali C, Tsakiris D. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatr Res. 1993;34(5):675–679. doi: 10.1203/00006450-199311000-00022. - DOI - PubMed
    1. Emmerson AJ, Coles HJ, Stern CM, Pearson TC. Double blind trial of recombinant human erythropoietin in preterm infants. Arch Dis Child. 1993;68(3 Spec No):291–296. doi: 10.1136/adc.68.3_Spec_No.291. - DOI - PMC - PubMed

Publication types

MeSH terms